All sponsors

Guangzhou Lupeng Pharmaceutical Company LTD.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS0
Open Guangzhou Lupeng Pharmaceutical Company LTD. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Rocbrutinib
NCT05716087
P2Active, not recruitingMantle Cell Lymphoma (MCL)622024-12-05 (+9 mo)
Rocbrutinib
NCT07189065
P2RecruitingDiffuse Large B-Cell Lymphoma (DLBCL)1502027-12-31
Lacutoclax
NCT07609823
P2RecruitingRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma752028-03-30
Rocbrutinib
NCT07776743
P2RecruitingRelapsing-remitting Multiple Sclerosis (RRMS)302028-06
Lacutoclax+Rocbrutinib
NCT07609862
P1/2RecruitingMantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL)922029-06-30
Rocbrutinib
NCT07377578
P3RecruitingMantle Cell Lymphoma3942031-05-30